igm
biosciences
present
first
clinical
data
lymphoma
ash
annual
meeting
mountain
view
globe
newswire
igm
biosciences
nasdaq
igms
biotechnology
company
focused
creating
developing
engineered
igm
antibodies
today
announced
expects
first
clinical
data
phase
trial
evaluating
presented
american
society
hematology
ash
annual
meeting
exposition
held
virtually
bispecific
igm
antibody
targeting
protein
surface
lymphoma
cells
protein
surface
cells
order
kill
lymphoma
cells
patients
lymphoma
nhl
company
multicenter
phase
clinical
trial
intended
assess
safety
pharmacokinetics
preliminary
efficacy
intravenous
patients
relapsed
refractory
b
cell
nhl
preliminary
results
expected
presented
saturday
december
pt
oral
poster
presentation
titled
preliminary
results
phase
dose
escalation
study
igm
based
bispecific
antibody
x
patients
advanced
time
ash
annual
meeting
igm
plans
present
additional
safety
pharmacokinetic
biomarker
efficacy
data
eight
patients
described
abstract
released
today
budde
et
abstract
additional
patients
treated
subsequent
data
abstract
igm
currently
enrolling
patients
treatment
mg
data
dose
cohort
available
time
ash
annual
meeting
described
abstract
june
eight
patients
treated
dose
levels
mg
eight
patients
received
average
four
prior
therapies
treatment
six
eight
patients
remained
active
treatment
data
abstract
dose
limiting
toxicities
dlts
drug
related
serious
adverse
events
saes
observed
among
eight
patients
two
patients
experienced
transient
fevers
grade
higher
cytokine
release
syndrome
observed
among
eight
patients
cytokines
detectable
following
dosing
transient
returned
baseline
less
hours
ifng
primary
cytokine
observed
significant
levels
detected
one
patient
preliminary
results
cell
engaging
antibody
study
show
improved
safety
tolerability
profile
also
evidence
novel
mechanism
action
based
repeatable
cell
activation
preservation
cell
function
compared
cell
engaging
antibodies
pleased
clinical
data
described
abstract
clinical
testing
engineered
igm
antibody
said
fred
schwarzer
chief
executive
officer
igm
biosciences
believe
data
provide
important
initial
validation
igm
cell
engaging
bispecific
technology
broader
igm
antibody
technology
platform
look
forward
continued
development
extensive
pipeline
igm
encouraging
see
evidence
repeatable
immune
activation
cells
said
daniel
chen
chief
medical
officer
igm
biosciences
contrast
cell
activation
profile
cell
engagers
cells
suggests
activating
cells
manner
different
igg
cell
engagers
preserves
cell
function
repeatable
cell
activation
look
forward
presenting
initial
clinical
results
ash
continuing
development
applying
novel
cell
engager
technology
additional
hematologic
solid
tumor
targets
igm
biosciences
headquartered
mountain
view
california
igm
biosciences
biotechnology
company
focused
creating
developing
engineered
igm
antibodies
since
igm
biosciences
worked
overcome
manufacturing
protein
engineering
hurdles
limited
therapeutic
use
igm
antibodies
efforts
igm
biosciences
created
proprietary
igm
technology
platform
development
igm
antibodies
clinical
indications
inherent
properties
may
provide
advantages
compared
igg
antibodies
cautionary
note
regarding
statements
press
release
contains
statements
including
statements
relating
igm
plans
expectations
forecasts
future
events
statements
include
limited
potential
expectations
regarding
company
igm
technology
platform
igm
antibodies
statements
regarding
company
phase
clinical
trial
timing
reporting
initial
clinical
data
phase
trial
presentation
initial
clinical
data
phase
trial
ash
annual
meeting
december
company
development
strategy
statements
igm
chief
executive
officer
chief
medical
officer
statements
subject
numerous
important
factors
risks
uncertainties
may
cause
actual
events
results
differ
materially
including
limited
potential
delays
disruption
resulting
pandemic
governmental
responses
pandemic
igm
early
stages
clinical
drug
development
risks
related
use
engineered
igm
antibodies
novel
unproven
therapeutic
approach
risk
igm
product
candidates
may
cause
significant
adverse
events
toxicities
undesirable
side
effects
potential
clinical
trials
future
clinical
trials
product
candidates
differ
preclinical
preliminary
expected
results
risk
initial
interim
topline
preliminary
data
igm
clinical
trials
may
change
patient
data
become
available
subject
audit
verification
procedures
could
result
material
changes
later
final
data
igm
ability
adequately
demonstrate
sufficient
safety
efficacy
product
candidates
igm
ability
advance
product
candidates
successfully
complete
clinical
trials
timelines
projects
risk
necessary
regulatory
approvals
obtained
igm
ability
enroll
patients
ongoing
future
clinical
trials
igm
ability
successfully
manufacture
supply
product
candidates
clinical
trials
igm
ability
obtain
additional
capital
finance
operations
needed
uncertainties
related
projections
size
patient
populations
suffering
diseases
igm
targeting
igm
ability
obtain
maintain
protect
intellectual
property
rights
developments
relating
igm
competitors
industry
including
competing
product
candidates
therapies
general
economic
market
conditions
risks
uncertainties
including
fully
described
igm
filings
securities
exchange
commission
sec
including
igm
annual
report
form
filed
sec
march
igm
quarterly
report
form
filed
sec
august
igm
future
reports
filed
sec
statements
contained
press
release
speak
date
hereof
igm
specifically
disclaims
obligation
update
statement
except
required
law
contact
argot
partners
david
pitts
igmbio
